Please use a PC Browser to access Register-Tadawul
Get It
Takeda FY2024 Guidance Raised: Core Revenue And Profit Now Expected To Grow Low Single Digits; Core EPS Revised To Flat/Slight Decline. Free Cash Flow Raised To ¥550B–¥650B.
Takeda Pharmaceutical Company Limited +0.15%
Takeda Pharmaceutical Company Limited TAK | 13.66 | +0.15% |
FY2024 Outlook
Updating Full Year Management Guidance and Reported and Core Forecasts
Takeda has upgraded its FY2024 Management Guidance, primarily driven by product momentum and OPEX savings. In addition, and also reflecting revised foreign exchange assumptions for the year, Takeda has raised its FY2024 reported and Core forecasts from the previous forecast. For more details, see release: Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)
| FY2024 Management Guidance Core Change at CER (Non-IFRS) | ||
| FY2024 PREVIOUS MANAGEMENT GUIDANCE (October 2024) |
FY2024 REVISED MANAGEMENT GUIDANCE (January 2025) |
|
| Core Revenue | Flat to slightly increasing | Low-single-digit % increase |
| Core Operating Profit | Mid-single-digit % decline | Low-single-digit % increase |
| Core EPS (Yen) | Approx 10% decline | Flat to slightly declining |
| FY2024 Reported and Core Forecasts | ||
| (Billion yen, except percentages and per share amounts) | ||
FY2024 (October 2024) |
FY2024 REVISED FORECAST (January 2025) |
|
| Revenue | 4,480.0 | 4,590.0 |
| Core Revenue (Non-IFRS) | 4,480.0 | 4,590.0 |
| Operating Profit | 265.0 | 344.0 |
| Core Operating Profit (Non-IFRS) | 1,050.0 | 1,150.0 |
| Net Profit | 68.0 | 118.0 |
| EPS (Yen) | 43 | 75 |
| Core EPS (Yen) (Non-IFRS) | 456 | 507 |
| Adjusted Free Cash Flow (Non-IFRS) | 400.0-500.0 | 550.0-650.0 |
| Annual Dividend per Share (Yen) | 196 | 196 |